Action CRBP CORBUS PHARMACEUTICALS HOLDINGS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Corbus Pharmaceuticals Holdings, Inc.

Actions

CRBP

US21833P3010

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 03/05/2024 		Varia. 5j. Varia. 1 janv.
38,77 USD +1,49% Graphique intraday de Corbus Pharmaceuticals Holdings, Inc. +13,20% +541,89%
02/04 Corbus Pharmaceuticals Holdings, Inc. annonce le dosage du premier patient dans l'essai clinique américain de phase 1 de son ADC de nouvelle génération ciblant la Nectine-4 CI
13/03 Corbus Pharmaceuticals dépose une déclaration d'enregistrement mixte MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
Certain Restricted Stock Units of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
Certain Warrants of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
Certain Options of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
Certain Common Stock of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Corbus Pharmaceuticals Files Mixed Shelf
Health Care Climbs on Risk Appetite -- Health Care Roundup
Corbus Pharmaceuticals: Q4 Earnings Snapshot
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
North American Morning Briefing : Inflation Data -2-
North American Morning Briefing : Powell Still in -2-
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CRBP
  4. Actualités Corbus Pharmaceuticals Holdings, Inc.
  5. Autres langues